Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Expects Strong Patient Benefits To Propel Victoza Sales In India But Will Pricing Get In The Way?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Enthused by better-then-expected performance of its latest GLP-1 agonist Victoza (liraglutide) in the U.S., Novo Nordisk hopes that its new offering will find wide acceptance among Indian diabetologists and endocrinologists as it gears up for a nationwide launch. In addition to the U.S., Canada, India and E.U., Victoza has been introduced in a short span of time in 11 countries and will soon be available in Japan

You may also be interested in...



Novo Nordisk Flaunts Tresiba To Outsmart Sanofi’s Lantus In India

After widening the gap with competitors in the insulin market by a huge margin, Novo Nordisk is preparing to launch Tresiba and take a shot at the long-acting basal insulin market, a stronghold preserved by Sanofi globally. Will Tresiba firmly establish Novo Nordisk as the unquestionable insulin leader?

India's Cadila Seeks To Cut The Pain Of GLP-1 Injectables As It Goes For Safety Studies Of Novel Oral Compound

MUMBAI - It may be early days but researchers at the sprawling Zydus Research Center located near the Western Indian city of Ahmedabad are upbeat about their latest finding - a novel orally administered GLP-1 agonist named ZYOG1- now ready to be tested on humans

India's Cadila Seeks To Cut The Pain Of GLP-1 Injectables As It Goes For Safety Studies Of Novel Oral Compound

MUMBAI - It may be early days but researchers at the sprawling Zydus Research Center located near the Western Indian city of Ahmedabad are upbeat about their latest finding - a novel orally administered GLP-1 agonist named ZYOG1- now ready to be tested on humans

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel